TWI461191B - 單種或組合型植物-大麻素於治療癲癇的用途 - Google Patents

單種或組合型植物-大麻素於治療癲癇的用途 Download PDF

Info

Publication number
TWI461191B
TWI461191B TW099121811A TW99121811A TWI461191B TW I461191 B TWI461191 B TW I461191B TW 099121811 A TW099121811 A TW 099121811A TW 99121811 A TW99121811 A TW 99121811A TW I461191 B TWI461191 B TW I461191B
Authority
TW
Taiwan
Prior art keywords
seizures
thcv
cbd
animals
ptz
Prior art date
Application number
TW099121811A
Other languages
English (en)
Chinese (zh)
Other versions
TW201105318A (en
Inventor
班 懷利
蓋瑞 史蒂芬
克拉蕊 威廉斯
傑佛瑞 蓋伊
史蒂芬 懷特
菊地哲朗
Original Assignee
Ｇｗ伐瑪有限公司
大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41008705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI461191(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ｇｗ伐瑪有限公司, 大塚製藥股份有限公司 filed Critical Ｇｗ伐瑪有限公司
Publication of TW201105318A publication Critical patent/TW201105318A/zh
Application granted granted Critical
Publication of TWI461191B publication Critical patent/TWI461191B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
TW099121811A 2009-07-03 2010-07-02 單種或組合型植物-大麻素於治療癲癇的用途 TWI461191B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
TW201105318A TW201105318A (en) 2011-02-16
TWI461191B true TWI461191B (zh) 2014-11-21

Family

ID=41008705

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099121811A TWI461191B (zh) 2009-07-03 2010-07-02 單種或組合型植物-大麻素於治療癲癇的用途

Country Status (28)

Country Link
US (4) US9066920B2 (cg-RX-API-DMAC10.html)
EP (3) EP2448637B2 (cg-RX-API-DMAC10.html)
JP (2) JP5904938B2 (cg-RX-API-DMAC10.html)
KR (1) KR101727000B1 (cg-RX-API-DMAC10.html)
CN (2) CN106236744A (cg-RX-API-DMAC10.html)
AR (1) AR077448A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010267775C1 (cg-RX-API-DMAC10.html)
BR (1) BR112012000076A2 (cg-RX-API-DMAC10.html)
CA (2) CA2766082C (cg-RX-API-DMAC10.html)
CY (1) CY1115338T1 (cg-RX-API-DMAC10.html)
DK (1) DK2448637T4 (cg-RX-API-DMAC10.html)
ES (1) ES2460623T5 (cg-RX-API-DMAC10.html)
GB (3) GB2471523A (cg-RX-API-DMAC10.html)
HR (1) HRP20140398T4 (cg-RX-API-DMAC10.html)
IL (1) IL217280B (cg-RX-API-DMAC10.html)
IN (1) IN2012DN00804A (cg-RX-API-DMAC10.html)
MX (1) MX2012000257A (cg-RX-API-DMAC10.html)
MY (1) MY156759A (cg-RX-API-DMAC10.html)
NZ (2) NZ620838A (cg-RX-API-DMAC10.html)
PL (1) PL2448637T5 (cg-RX-API-DMAC10.html)
PT (1) PT2448637E (cg-RX-API-DMAC10.html)
RU (1) RU2563143C2 (cg-RX-API-DMAC10.html)
SG (1) SG176914A1 (cg-RX-API-DMAC10.html)
SI (1) SI2448637T2 (cg-RX-API-DMAC10.html)
TW (1) TWI461191B (cg-RX-API-DMAC10.html)
UA (1) UA108852C2 (cg-RX-API-DMAC10.html)
WO (1) WO2011001169A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201200373B (cg-RX-API-DMAC10.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) * 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
US11062795B2 (en) 2007-03-02 2021-07-13 Enigami Systems, Inc. Healthcare data system
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10406186B2 (en) 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2981285A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US20160317468A1 (en) * 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
MX385238B (es) 2015-11-24 2025-03-14 Constance Therapeutics Inc Composiciones de aceite de cannabis y metodos para preparacion de las mismas.
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3471746A4 (en) 2016-06-15 2020-02-26 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS
CA3010636A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
WO2021055499A1 (en) * 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022026613A2 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
EP4376893A2 (en) 2021-07-29 2024-06-05 Emory University Phosphate prodrugs of cannabinoids
WO2023200906A1 (en) * 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders
CA3264785A1 (en) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
MXPA05001621A (es) 2002-08-14 2005-08-19 Gw Pharma Ltd Extraccion de cannabinoides farmaceuticamente activos de materiales vegetales.
EP1542657B8 (en) * 2002-08-14 2012-03-14 GW Pharma Limited Cannabinoid liquid formulations for mucosal amdinistration
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
US9023322B2 (en) 2008-03-26 2015-05-05 Stichting Sanammad Chewing gum compositions comprising cannabinoids
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
EP2747770A1 (en) 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jomar M. Cunha et al.;"Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients";Pharmacology,1980,vol.21,pages 175-185. *

Also Published As

Publication number Publication date
GB0911580D0 (en) 2009-08-12
EP2448637B1 (en) 2014-03-12
WO2011001169A1 (en) 2011-01-06
CA2766082A1 (en) 2011-01-06
HRP20140398T4 (hr) 2022-10-14
MY156759A (en) 2016-03-31
PL2448637T5 (pl) 2022-10-03
JP2012532093A (ja) 2012-12-13
ES2460623T3 (es) 2014-05-14
AU2010267775A1 (en) 2012-02-23
EP2448637A1 (en) 2012-05-09
RU2012103603A (ru) 2013-08-10
SG176914A1 (en) 2012-01-30
PT2448637E (pt) 2014-05-27
AR077448A1 (es) 2011-08-31
CA3040410C (en) 2023-03-28
ZA201200373B (en) 2012-09-26
AU2010267775B2 (en) 2016-10-06
AU2010267775C1 (en) 2020-02-27
NZ597704A (en) 2014-05-30
CA2766082C (en) 2019-06-11
US9522123B2 (en) 2016-12-20
MX2012000257A (es) 2012-01-27
HRP20140398T1 (hr) 2014-06-20
IN2012DN00804A (cg-RX-API-DMAC10.html) 2015-06-26
GB201010897D0 (en) 2010-08-11
SI2448637T2 (sl) 2022-10-28
NZ620838A (en) 2015-08-28
US20150335590A1 (en) 2015-11-26
US20190247324A1 (en) 2019-08-15
KR20120088648A (ko) 2012-08-08
UA108852C2 (ru) 2015-06-25
RU2563143C2 (ru) 2015-09-20
GB2471565B (en) 2012-07-04
DK2448637T4 (da) 2022-09-12
US20170273913A1 (en) 2017-09-28
TW201105318A (en) 2011-02-16
GB2471565A (en) 2011-01-05
IL217280A0 (en) 2012-02-29
SI2448637T1 (sl) 2014-07-31
US20120165402A1 (en) 2012-06-28
CN106236744A (zh) 2016-12-21
GB2485291A (en) 2012-05-09
GB2485291B (en) 2013-03-27
DK2448637T3 (da) 2014-05-26
EP3718603A1 (en) 2020-10-07
GB201121919D0 (en) 2012-02-01
PL2448637T3 (pl) 2014-08-29
JP2016166205A (ja) 2016-09-15
CN102596322A (zh) 2012-07-18
GB2471523A (en) 2011-01-05
ES2460623T5 (es) 2022-10-14
CY1115338T1 (el) 2017-01-04
JP5904938B2 (ja) 2016-04-20
BR112012000076A2 (pt) 2020-06-02
IL217280B (en) 2018-05-31
EP2727626A1 (en) 2014-05-07
HK1164766A1 (en) 2012-09-28
EP2448637B2 (en) 2022-06-08
KR101727000B1 (ko) 2017-05-02
US9066920B2 (en) 2015-06-30
CA3040410A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
US9522123B2 (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US12121499B2 (en) Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
TWI583374B (zh) 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
HK40040800A (en) Use of one or a combination of phytocannabinoids in the treatment of epilepsy
HK1195750A (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
HK1164766B (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
NZ622424B2 (en) A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees